ClinicalTrials.gg
CompletedNCT02925299DAN05Updated Oct 15, 2026Results posted

Day and Night Closed-loop in Young People With Type 1 Diabetes

An interventional study of FlorenceM (US) and FlorenceX (UK) and Insulin pump therapy in Diabetes Mellitus, Diabetes Mellitus, Type 1 and Glucose Metabolism Disorders, sponsored by Jaeb Center for Health Research. Completed at 11 sites in 2 countries. Open to participants aged 6 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Primary conditionDiabetes Mellitus, Type 1Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 1
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 1, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Jaeb Center for Health Research · Not applicable, Interventional, and Treatment

How we know

Updated Oct 15, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
133
Allocation
Randomized
Ages
6 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies in Diabetes Mellitus, Type 1 by Jaeb Center for Health Research — 1 open to participants now, 2 under way, none of them phase 3. Diabetes Mellitus, Type 1 · Jaeb Center for Health Research.

Enrollment
11th of 29
133 · median 74
Started
2017
with 2 others
No phase
10 of 36
1 open now
Registered
27th of 36
by date

Among the 36 studies in Diabetes Mellitus, Type 1 by Jaeb Center for Health Research, this one is the 11th largest by enrollment of the 29 interventional ones that give a count, is one of 3 that started in 2017, is one of 10 with no phase, and was the 27th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

1 of the 36 studies in Diabetes Mellitus, Type 1 by Jaeb Center for Health Research is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 6 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Diabetes Mellitus, Type 1 by Jaeb Center for Health Research, or all of them as a file.
02

Study summary

The main study objective is to determine whether 24/7 automated closed-loop glucose control combined with low glucose feature will improve glucose control as measured by HbA1c.

This is an open-label, multi-centre, multi-national, single-period, randomised, parallel group design study, involving a 6 month period of home study during which day and night glucose levels will be controlled either by a closed-loop system combined with low glucose feature (intervention group) or by insulin pump therapy alone (control group).

It is expected that a total of up to 150 subjects (aiming for 130 randomised subjects) with type 1 diabetes will be recruited through paediatric outpatient diabetes clinics of the investigation centres. Participants will all be on subcutaneous insulin pump therapy.

Subjects in the intervention group will have proven competencies both in the use of the study insulin pump and the study continuous glucose monitoring (CGM) device, and will receive appropriate training in the safe use of closed-loop insulin delivery system and low glucose feature. All subjects will have regular contact with the study team during the home study phase including 24/7 telephone support. The primary outcome is between group differences in HbA1c levels at 6 months post study arm initiation. Secondary outcomes are the time spent in the glucose target (3.9 to 10.0mmol/l; 70 to 180mg/dl), time spent with glucose levels above and below target, as recorded by CGM, and other CGM-based metrics. Safety evaluation comprises assessment of the frequency of severe hypoglycaemic episodes and diabetic ketoacidosis (DKA).

Read the detailed description
  • Purpose of the study: To determine whether 24/7 automated closed-loop glucose control will improve glucose control as measured by glycated haemoglobin and reduce the burden of hypoglycaemia compared to insulin pump therapy alone.
  • Study Objectives:

    1. EFFICACY: The objective is to assess efficacy of day and night automated closed-loop glucose control in improving glucose control as measured by glycated haemoglobin, as compared to insulin pump therapy alone.
    2. SAFETY: The objective is to evaluate the safety of day and night automated closed-loop glucose control, in terms of episodes of severe hypoglycaemia and other adverse events.
    3. UTILITY: The objective is to determine the frequency and duration of the use of the automated closed-loop system.
    4. HUMAN FACTORS: The objective is to assess cognitive, emotional, and behavioural characteristics of participating subjects and family members and their response to the closed-loop system and clinical trial using validated surveys and focus groups.
    5. HEALTH ECONOMICS: The objective is to perform a cost utility analysis to inform reimbursement decision-making.
  • Study Design: An open-label, multi-centre, randomised, single-period parallel study, contrasting day-and-night automated closed-loop glucose control with insulin pump therapy alone.
  • Population: 130 participants randomised (equal proportion of those aged 6 to 12 years and 13 to 18 years, a minimum quota of 25% participants with baseline HbA1c >8.5%)
  • Maximum duration of study for a subject: 8 months
  • Recruitment: The subjects will be recruited through the pediatric outpatient clinics at each center.
  • Consent: Written consent / assent will be obtained from participants and/or guardians according to REC / IRB requirements
  • Screening Assessments: Eligible participants will undergo a screening evaluation where blood samples for full blood count, liver, thyroid function and anti-transglutaminase antibodies (with IgA levels if not done within previous 12 months) will be taken. Non-hypoglycaemia C-peptide, glucose and HbA1c will also be measured, and a urine pregnancy test in females of child-bearing potential will be performed.

Surveys investigating participants' quality of life, psychosocial and cognitive functioning, and response to their current treatment will be distributed.

Participants will be fitted with a blinded continuous glucose monitoring (CGM) device to assess baseline glycaemic control. Instructions on how to safely use, remove and send back the device will be provided.

  • Study Training: Training sessions on the use of study CGM, insulin pump (and closed loop system for those randomized to be intervention group) will be provided by the research team. Training session on the use of real-time CGM and on how to interpret real-time and retrospective stored data will be provided to all subjects / carers using written material.
  • Run-In Period: During a 1-2 week run-in period, subjects will continue using their own insulin pump. Data obtained from blinded CGM and pump downloads may be utilised for therapy adjustment.
  • Competency Assessment: Competency on the use of study insulin pump and study CGM will be evaluated using a competency assessment tool developed by the research team. Further training may be delivered as required.
  • Randomization: Eligible subjects will be randomised using randomisation software to the use of real-time CGM and low glucose feature combined with day and night closed-loop or to conventional insulin pump therapy alone.

A blood sample will be taken for the measurement of HbA1c and a urine pregnancy test in females of child-bearing potential. A blood sample for centralised analysis of HbA1c will be taken if screening and randomisation are >28 days apart.

  1. Automated day and night closed-loop insulin delivery (intervention arm) combined with low glucose feature (interventional arm) - Participants in the closed-loop group will receive additional training sessions following randomisation covering the use of the study insulin pump and real-time CGM, prior to starting closed-loop insulin delivery.

    Once confident with the use of the study pump and CGM system, participants will receive training required for safe and effective use of the closed-loop system approximately 2-4 weeks after randomisation. During this 2-4 hour session participants will operate the system under the supervision of the clinical team. Competency on the use of closed-loop system will be evaluated.

    Thereafter, participants are expected to use closed-loop for 6 months without direct real-time remote monitoring.

  2. Insulin pump therapy (control arm) - Refresher training on key aspects of insulin pump therapy will be provided.

Subjects will continue using their own insulin pump for 6 months.

  • 3-month and 6 month assessments:

    1. A blood sample will be taken for measurement of HbA1c and a urine pregnancy test in females of child-bearing potential.
    2. Validated surveys evaluating the impact of the devices employed on quality of life, psychosocial and cognitive functioning, diabetes management and treatment satisfaction will be completed.
    3. Participants of both study arms will be fitted with blinded CGM systems at the end of each follow up visit. The sensors will be worn at home for up to 14 days and will be sent back to the research team.

    6 months only: Subjects/guardians will be invited to join follow-up focus groups to gather feedback and reactions to their current treatment (closed-loop or insulin pump), the clinical trial, and quality of life changes.

  • Study Contacts: In between study visits, participants will be contacted by the study team (email or phone) once monthly in order to record any adverse events, device deficiencies, and changes in insulin settings, other medical conditions and/or medication.

In case of any technical device or problems related to diabetes management such as hypo- or hyperglycaemia, subjects will be able to contact a 24-hour telephone helpline to the local research team at any time. The local research team will have access to central 24 hour advice on technical issues.

--Procedures for safety monitoring during trial: Standard operating procedures for monitoring and reporting of all adverse events will be in place, including serious adverse events (SAE), serious adverse device effects (SADE) and specific adverse events (AE) such as severe hypoglycaemia.

Subjects will be asked to test and record blood ketones if their finger prick glucose is > 16.7mmol/l (300mg/dl) upon awakening, >300 for more than 1 hour, or >22.2mmo/l (400mg/dL) at any time as part of the safety assessment for DKA.

A data safety and monitoring board (DSMB) will be informed of all serious adverse events and any unanticipated serious adverse device effects that occur during the study and will review compiled adverse event data at periodic intervals.

--Criteria for withdrawal of patients on safety grounds: A subject, parent, or guardian may terminate participation in the study at any time without necessarily giving a reason and without any personal disadvantage. An investigator can stop the closed-loop intervention after consideration of the benefit/risk ratio. Possible reasons are:

  1. Serious adverse events
  2. Significant protocol violation or non-compliance
  3. Failure to satisfy competency assessment
  4. Decision by the investigator, or the sponsor, that termination is in the subject's best medical interest
  5. Pregnancy, planned pregnancy, or breast feeding
  6. Allergic reaction to insulin

Efforts will be made to retain subjects in follow up for the final primary outcome assessment even if the intervention is discontinued, unless the investigator believes that it will be harmful for the subject to continue in the trial.

03

Conditions studied

  • Diabetes Mellitus
  • Diabetes Mellitus, Type 1
  • Glucose Metabolism Disorders
  • Endocrine System Diseases
  • Autoimmune Diseases
04

In context

Diabetes Mellitus, Type 1 Reclassified

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

This study's enrollment of 133 is above the median of 40 across 2,824 interventional studies indexed under Diabetes Mellitus, Type 1.

Browse Diabetes Mellitus, Type 1 studies →

Lead sponsor

Jaeb Center for Health Research is the lead sponsor of 129 studies on the registry; 16 are open to participants now.

Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.

Compared within Diabetes Mellitus, Type 1, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
6 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥6 and \<19 years
  2. Type 1 diabetes as defined by WHO (51) for at least 1 year [WHO definition: 'The aetiological type named type 1 encompasses the majority of cases with are primarily due to beta-cell destruction, and are prone to ketoacidosis. Type 1 includes those cases attributable to an process, as well as those with beta-cell destruction for which neither an aetiology nor a pathogenesis is known (idiopathic). It does not include those forms of beta-cell destruction or failure to which specific causes can be assigned (e.g. cystic fibrosis, mitochondrial defects, etc.).']
  3. Use of an insulin pump for at least 3 months, with good knowledge of insulin self-adjustment by subject or caregiver as judged by the investigator
  4. Using U-100 rapid acting insulin analogues insulin Aspart or Lispro only
  5. Willing to perform regular finger-prick blood glucose monitoring, with at least 4 blood glucose measurements per day day
  6. Screening ≥ 7.0% (53 mmol/mol) and ≤10 % (86mmol/mol) based on analysis from local laboratory
  7. Literate in English
  8. Willing to wear glucose sensor
  9. Willing to wear closed-loop system at home
  10. Willing to follow study specific instructions
  11. Willing to upload pump and CGM data at regular intervals
  12. Access to WiFi.
  13. Lives with someone who is trained to administer intramuscular glucagon and is able to seek emergency assistance

Exclusion criteria

Exclusion Criteria:

  1. Living alone
  2. Current use of any closed-loop system
  3. Any other physical or psychological disease likely to interfere with the normal conduct of the study and interpretation of the study results as judged by the investigator
  4. Untreated coeliac disease, adrenal insufficiency, or untreated thyroid disease
  5. Current treatment with drugs known to interfere with glucose metabolism, e.g. systemic , non-selective beta-blockers and MAO inhibitors etc.
  6. Known or suspected allergy to insulin
  7. nephropathy ( \< 45ml/min) or on dialysis, neuropathy or active retinopathy (defined as presence of maculopathy or proliferative changes) as judged by the investigator
  8. Recurrent incidents of severe hypoglycaemia (>1 episode) during the previous 6 months (adolescents: severe hypoglycaemia is defined as an event requiring assistance of another person to actively administer carbohydrates, glucagon, or take other corrective actions including episodes of hypoglycaemia severe enough to cause unconsciousness, seizures or attendance at hospital; children: severe hypoglycaemia is defined as an event associated with a seizure or loss of consciousness)
  9. Recurrent incidents of diabetic ketoacidosis (>1 episode) during previous 6 months
  10. Unwilling to avoid regular use of acetaminophen
  11. Lack of reliable telephone facility for contact
  12. Total daily insulin dose ≥ 2 IU/kg/day
  13. Total daily insulin dose \< 15 IU/day
  14. Pregnancy, planned pregnancy, or breast feeding
  15. Severe visual impairment
  16. Severe hearing impairment
  17. Seizure disorder
  18. Medically documented allergy towards the adhesive (glue) of plasters or unable to tolerate tape adhesive in the area of sensor placement
  19. Serious skin diseases (e.g. psoriasis vulgaris, bacterial skin diseases) located at places of the body, which potentially are possible to be used for localisation of the glucose sensor)
  20. Illicit drugs abuse
  21. Subject is currently abusing prescription drugs
  22. Alcohol abuse
  23. Use of pramlintide (Symlin), or other non-insulin glucose lowering agents including sulphonylureas, biguanides, DPP4-Inhibitors, , GLP-1 analogues, SGLT-1/ 2 inhibitors at time of screening
  24. Shift work with working hours between 10pm and 8am
  25. Sickle cell disease, haemoglobinopathy, or has received red blood cell transfusion or erythropoietin within 3 months prior to time of screening
  26. Eating disorder such as anorexia or bulimia
  27. Employed by Medtronic Diabetes or with immediate family members employed by Medtronic Diabetes
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
133 participants (actual)

Study arms

  • Experimental
    24/7 closed loop insulin delivery

    The study system includes (1) a CGM that measures glucose levels, (2) a computer program on a smartphone that determines how much insulin is needed, and (3) an insulin pump that delivers the insulin. The name of this closed-loop system used in the US is FlorenceM (Medtronic 640G pump and Guardian3 sensor). The name of this closed-loop system in the UK is FlorenceX (DANA pump and Dexcom sensor). Half of the individuals taking part in the study will use the closed-loop study system for 6 months.

    Device: FlorenceM (US) and FlorenceX (UK)

  • Active comparator
    Insulin pump therapy

    Half of the Subjects will continue using their own insulin pump for 6 months.

    Device: Insulin pump therapy

Interventions

  • DeviceFlorenceM (US) and FlorenceX (UK)

    The automated closed loop system (FlorenceM in US) will consist of: Next generation sensor augmented Medtronic insulin pump 640G (Medtronic Minimed, CA, USA) incorporating the Medtronic Guardian3 CGM and glucose suspend feature. The automated closed loop system (FlorenceX in UK) will consist of: The DANA Diabecare R insulin pump (Sooil Development, Korea) incorporating the Dexcom G6 CGM. An Android smartphone containing the Cambridge model predictive algorithm and communicating wirelessly with the insulin pump using a proprietary translator device.

  • DeviceInsulin pump therapy

    Subjects will continue using their own insulin pump for 6 months.

07

What researchers measure

Primary outcomes

  1. Glycated Hemoglobin (HbA1c) at 6 Months.

    The objective is to assess efficacy of day and night automated closed-loop glucose control combined with low glucose feature in improving HbA1c, as compared with insulin pump therapy alone.

    Time frame: HbA1c at 6 months

Secondary outcomes

  1. Time Spent in the Target Glucose Range (3.9 to 10mmol/l) (70 to 180mg/dl)

    Secondary endpoints regarding glucose levels will be based on sensor glucose data.

    Time frame: 6 months

  2. Time Spent Below Target Glucose (3.9mmol/l)(70mg/dl)

    Secondary endpoints regarding glucose levels will be based on sensor glucose data.

    Time frame: 6 months

  3. Time Spent Above Target Glucose (10.0 mmol/l) (180 mg/dl)

    Secondary endpoints regarding glucose levels will be based on sensor glucose data.

    Time frame: 6 months

  4. Mean and Standard Deviation Sensor Glucose

    Secondary endpoints regarding glucose levels will be based on sensor glucose data.

    Time frame: 6 months

  5. Time With Glucose Levels < 3.5 mmol/l (63 mg/dl)

    Secondary endpoints regarding glucose levels will be based on sensor glucose data.

    Time frame: 6 months

  6. Time With Glucose Levels <3.0 mmol/l (54 mg/dl)

    Secondary endpoints regarding glucose levels will be based on sensor glucose data.

    Time frame: 6 months

  7. Time With Glucose Levels in Significant Hyperglycaemia (Glucose Levels > 16.7 mmol/l) (300mg/dl)

    Secondary endpoints regarding glucose levels will be based on sensor glucose data.

    Time frame: 6 months

  8. Total Daily Insulin

    Units/kg per day

    Time frame: 6 months

  9. HbA1c <53 mmol/Mol (<7.0%)

    Participants with HbA1c \<53 mmol/mol (\<7.5%) at 6 months

    Time frame: 6 months

  10. HbA1c <58 mmol/Mol (<7.5%)

    Participants with HbA1c \<58 mmol/mol (\<7.5%) at 6 months

    Time frame: 6 months

  11. Relative Reduction ≥10%

    Relative reduction in HbA1c ≥10% at 6 months

    Time frame: 6 months

  12. HbA1c Absolute Reduction ≥0.5%

    HbA1c absolute reduction ≥0.5% from baseline to 6 months

    Time frame: 6 months

  13. HbA1c Absolute Reduction ≥1%

    HbA1c absolute reduction ≥1% from baseline to 6 months

    Time frame: 6 months

  14. HbA1c Absolute Reduction ≥1% or HbA1c <53 mmol/Mol (<7.0%)

    Time frame: 6 months

Other outcomes

  1. Safety Evaluation

    Frequency of severe hypoglycemic episodes as defined by American Diabetes Association (adolescents), and International Society for Pediatric and Adolescent Diabetes (children)

    Time frame: 6 months

08

Results

Posted Oct 15, 2026

Participant flow

Participant flow — Overall Study
Milestone24/7 Closed Loop Insulin DeliveryInsulin Pump Therapy
Started6568
Completed5964
Not completed64
Withdrew: Withdrawal by subject42
Withdrew: Device issues22

Outcome measures

PrimaryGlycated Hemoglobin (HbA1c) at 6 Months.

The objective is to assess efficacy of day and night automated closed-loop glucose control combined with low glucose feature in improving HbA1c, as compared with insulin pump therapy alone.

Time frame:
HbA1c at 6 months
Reported as:
Mean · mmol/mol
Glycated Hemoglobin (HbA1c) at 6 Months.
mmol/mol24/7 Closed Loop Insulin DeliveryInsulin Pump Therapy
Glycated Hemoglobin (HbA1c) at 6 Months.60 ± 1264 ± 8
SecondaryTime Spent in the Target Glucose Range (3.9 to 10mmol/l) (70 to 180mg/dl)

Secondary endpoints regarding glucose levels will be based on sensor glucose data.

Time frame:
6 months
Reported as:
Mean · percent of 24 hour period
Time Spent in the Target Glucose Range (3.9 to 10mmol/l) (70 to 180mg/dl)
percent of 24 hour period24/7 Closed Loop Insulin DeliveryInsulin Pump Therapy
Time Spent in the Target Glucose Range (3.9 to 10mmol/l) (70 to 180mg/dl)54 ± 1747 ± 12
SecondaryTime Spent Below Target Glucose (3.9mmol/l)(70mg/dl)

Secondary endpoints regarding glucose levels will be based on sensor glucose data.

Time frame:
6 months
Reported as:
Median · percent of 24 hour period
Time Spent Below Target Glucose (3.9mmol/l)(70mg/dl)
percent of 24 hour period24/7 Closed Loop Insulin DeliveryInsulin Pump Therapy
Time Spent Below Target Glucose (3.9mmol/l)(70mg/dl)6.1 (3.0 to 12.1)5.4 (2.0 to 12.0)
SecondaryTime Spent Above Target Glucose (10.0 mmol/l) (180 mg/dl)

Secondary endpoints regarding glucose levels will be based on sensor glucose data.

Time frame:
6 months
Reported as:
Mean · percent of 24 hour period
Time Spent Above Target Glucose (10.0 mmol/l) (180 mg/dl)
percent of 24 hour period24/7 Closed Loop Insulin DeliveryInsulin Pump Therapy
Time Spent Above Target Glucose (10.0 mmol/l) (180 mg/dl)38 ± 2046 ± 15
SecondaryMean and Standard Deviation Sensor Glucose

Secondary endpoints regarding glucose levels will be based on sensor glucose data.

Time frame:
6 months
Reported as:
Mean · mmol/L
Mean and Standard Deviation Sensor Glucose
mmol/L24/7 Closed Loop Insulin DeliveryInsulin Pump Therapy
Mean and Standard Deviation Sensor Glucose9.7 ± 2.910.1 ± 1.8
SecondaryTime With Glucose Levels < 3.5 mmol/l (63 mg/dl)

Secondary endpoints regarding glucose levels will be based on sensor glucose data.

Time frame:
6 months
Reported as:
Median · percent of 24 hour period
Time With Glucose Levels < 3.5 mmol/l (63 mg/dl)
percent of 24 hour period24/7 Closed Loop Insulin DeliveryInsulin Pump Therapy
Time With Glucose Levels < 3.5 mmol/l (63 mg/dl)7.4 (4.1 to 12.4)3.6 (1.0 to 11.6)
SecondaryTime With Glucose Levels <3.0 mmol/l (54 mg/dl)

Secondary endpoints regarding glucose levels will be based on sensor glucose data.

Time frame:
6 months
Reported as:
Median · percent of 24 hour period
Time With Glucose Levels <3.0 mmol/l (54 mg/dl)
percent of 24 hour period24/7 Closed Loop Insulin DeliveryInsulin Pump Therapy
Time With Glucose Levels <3.0 mmol/l (54 mg/dl)2.9 (1.6 to 6.1)1.4 (1.0 to 2.3)
SecondaryTime With Glucose Levels in Significant Hyperglycaemia (Glucose Levels > 16.7 mmol/l) (300mg/dl)

Secondary endpoints regarding glucose levels will be based on sensor glucose data.

Time frame:
6 months
Reported as:
Median · percent of 24 hour period
Time With Glucose Levels in Significant Hyperglycaemia (Glucose Levels > 16.7 mmol/l) (300mg/dl)
percent of 24 hour period24/7 Closed Loop Insulin DeliveryInsulin Pump Therapy
Time With Glucose Levels in Significant Hyperglycaemia (Glucose Levels > 16.7 mmol/l) (300mg/dl)2.8 (1.8 to 5.4)5.7 (3.1 to 11.3)
SecondaryTotal Daily Insulin

Units/kg per day

Time frame:
6 months
Reported as:
Mean · units per kg of 24 hour period
Total Daily Insulin
units per kg of 24 hour period24/7 Closed Loop Insulin DeliveryInsulin Pump Therapy
Total Daily Insulin1.09 ± 0.271.03 ± 0.57
SecondaryHbA1c <53 mmol/Mol (<7.0%)

Participants with HbA1c \<53 mmol/mol (\<7.5%) at 6 months

Time frame:
6 months
Reported as:
Number · participants
HbA1c <53 mmol/Mol (<7.0%)
participants24/7 Closed Loop Insulin DeliveryInsulin Pump Therapy
HbA1c <53 mmol/Mol (<7.0%)194
SecondaryHbA1c <58 mmol/Mol (<7.5%)

Participants with HbA1c \<58 mmol/mol (\<7.5%) at 6 months

Time frame:
6 months
Reported as:
Number · participants
HbA1c <58 mmol/Mol (<7.5%)
participants24/7 Closed Loop Insulin DeliveryInsulin Pump Therapy
HbA1c <58 mmol/Mol (<7.5%)3216
SecondaryRelative Reduction ≥10%

Relative reduction in HbA1c ≥10% at 6 months

Time frame:
6 months
Reported as:
Number · participants
Relative Reduction ≥10%
participants24/7 Closed Loop Insulin DeliveryInsulin Pump Therapy
Relative Reduction ≥10%228
SecondaryHbA1c Absolute Reduction ≥0.5%

HbA1c absolute reduction ≥0.5% from baseline to 6 months

Time frame:
6 months
Reported as:
Number · participants
HbA1c Absolute Reduction ≥0.5%
participants24/7 Closed Loop Insulin DeliveryInsulin Pump Therapy
HbA1c Absolute Reduction ≥0.5%3327
SecondaryHbA1c Absolute Reduction ≥1%

HbA1c absolute reduction ≥1% from baseline to 6 months

Time frame:
6 months
Reported as:
Number · participants
HbA1c Absolute Reduction ≥1%
participants24/7 Closed Loop Insulin DeliveryInsulin Pump Therapy
HbA1c Absolute Reduction ≥1%166
SecondaryHbA1c Absolute Reduction ≥1% or HbA1c <53 mmol/Mol (<7.0%)
Time frame:
6 months
Reported as:
Number · participants
HbA1c Absolute Reduction ≥1% or HbA1c <53 mmol/Mol (<7.0%)
participants24/7 Closed Loop Insulin DeliveryInsulin Pump Therapy
HbA1c Absolute Reduction ≥1% or HbA1c <53 mmol/Mol (<7.0%)239
Other pre-specifiedSafety Evaluation

Frequency of severe hypoglycemic episodes as defined by American Diabetes Association (adolescents), and International Society for Pediatric and Adolescent Diabetes (children)

Time frame:
6 months
Reported as:
Number · number of severe hypoglycemic events
Safety Evaluation
number of severe hypoglycemic events24/7 Closed Loop Insulin DeliveryInsulin Pump Therapy
Safety Evaluation43

Adverse events

Collected over 6 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
24/7 Closed Loop Insulin Delivery0/65 (0%)4/65 (6.2%)0/65 (0%)
Insulin Pump Therapy0/68 (0%)3/68 (4.4%)0/68 (0%)
Most frequent serious events
Most frequent serious events
Event24/7 Closed Loop Insulin DeliveryInsulin Pump Therapy
Severe hypoglycemiaEndocrine disorders4/653/68

Baseline characteristics

Age, Continuous
Age, Continuous(years)24/7 Closed Loop Insulin DeliveryInsulin Pump TherapyTotal
Mean131 ± 2.612.8 ± 2.913.0 ± 2.8
Sex: Female, Male
Sex: Female, Male(Participants)24/7 Closed Loop Insulin DeliveryInsulin Pump TherapyTotal
Female373976
Male282957
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)24/7 Closed Loop Insulin DeliveryInsulin Pump TherapyTotal
Hispanic or Latino044
Not Hispanic or Latino6564129
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)24/7 Closed Loop Insulin DeliveryInsulin Pump TherapyTotal
American Indian or Alaska Native000
Asian347
Native Hawaiian or Other Pacific Islander011
Black or African American033
White6053113
More than one race134
Unknown or Not Reported145
Glycated hemoglobin at screening
Glycated hemoglobin at screening(mmol/mol)24/7 Closed Loop Insulin DeliveryInsulin Pump TherapyTotal
Mean66 ± 867 ± 866 ± 8
09

Study locations

11 sites
  • Stanford University
    Palo Alto, California 95032, United States
  • University of Colorado Denver School of Medicine Barbara Davis Center
    Aurora, Colorado 80045, United States
  • Yale University
    Hartford, Connecticut 06520, United States
  • Nemours Children's Health System
    Jacksonville, Florida 32207, United States
  • Indiana University
    Indianapolis, Indiana 43202, United States
  • University of Cambridge
    Cambridge, Cambridgeshire County CB2 0QQ, United Kingdom
  • Nottingham Children's Hospital
    Nottingham, England NG5 1PB, United Kingdom
  • Southampton Children's Hospital
    Southampton, England SO16 6YD, United Kingdom
  • The Leeds Teaching Hospitals NHS Trust
    Leeds, West Yorkshire LS9 7TF, United Kingdom
  • Alder Hey Children's NHS Foundation Trust
    Liverpool, United Kingdom
  • Oxford Children's Hospital
    Oxford, United Kingdom
10

References and documents

Publications

  • Ware J, Boughton CK, Allen JM, Wilinska ME, Tauschmann M, Denvir L, Thankamony A, Campbell FM, Wadwa RP, Buckingham BA, Davis N, DiMeglio LA, Mauras N, Besser REJ, Ghatak A, Weinzimer SA, Hood KK, Fox DS, Kanapka L, Kollman C, Sibayan J, Beck RW, Hovorka R; DAN05 Consortium. Cambridge hybrid closed-loop algorithm in children and adolescents with type 1 diabetes: a multicentre 6-month randomised controlled trial. Lancet Digit Health. 2022 Apr;4(4):e245-e255. doi: 10.1016/S2589-7500(22)00020-6. Epub 2022 Mar 7. PubMed 35272971 ↗
  • Musolino G, Allen JM, Hartnell S, Wilinska ME, Tauschmann M, Boughton C, Campbell F, Denvir L, Trevelyan N, Wadwa P, DiMeglio L, Buckingham BA, Weinzimer S, Acerini CL, Hood K, Fox S, Kollman C, Sibayan J, Borgman S, Cheng P, Hovorka R. Assessing the efficacy, safety and utility of 6-month day-and-night automated closed-loop insulin delivery under free-living conditions compared with insulin pump therapy in children and adolescents with type 1 diabetes: an open-label, multicentre, multinational, single-period, randomised, parallel group study protocol. BMJ Open. 2019 Jun 3;9(6):e027856. doi: 10.1136/bmjopen-2018-027856. PubMed 31164368 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

11

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2017 to primary completion in Aug 2020, 39 months.

Results were first posted in Oct 2026, 6 years 1 month after primary completion.

Of 852 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's 39 months is above that.

Counting every sponsor, half of 957 studies reached it within 18 months; a quarter within 9 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2016
First posted
Oct 5, 2016
StartActual
May 12, 2017
Primary completionActual
Aug 27, 2020
CompletionActual
Aug 27, 2020
Results first posted
Oct 15, 2026
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 15, 2026
Enrollment
131→133
Oct 15, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedThe primary outcome is the centralised measurement of glycated haemoglobinGlycated Hemoglobin (HbA1c) at 6 monthsMonths.Time frame: HbA1c will be taken at baseline, 3 and 6 months → HbA1c at 6 months
Oct 15, 2026
Documents
Secondary outcomes
7 edited, 7 added, 8 removed, 1 description edited
What changed in the outcomes
  • EditedTime spentSpent in the target glucose rangeTarget Glucose Range (3.9 to 10mmol/l) (70 to 180mg/dl)Time frame: 6 months
  • EditedTime spent below target glucoseSpent Below Target Glucose (3.9mmol/l)(70mg/dl)Time frame: 6 months
  • EditedTime spent above target glucoseSpent Above Target Glucose (10.0 mmol/l) (180 mg/dl)Time frame: 6 months
  • EditedMean and standard deviation or percentiles sensor glucoseStandard Deviation Sensor GlucoseTime frame: 6 months
  • EditedTime with glucose levelsWith Glucose Levels < 3.5 mmol/l (63 mg/dl)Time frame: 6 months
  • EditedTime with glucose levelsWith Glucose Levels <3.0 mmol/l (54 mg/dl)Time frame: 6 months
  • EditedTime with glucose levelsWith Glucose Levels in significant hyperglycaemiaSignificant Hyperglycaemia (glucose levelsGlucose Levels > 16.7 mmol/l) (300mg/dl)Time frame: 6 months
  • AddedTotal Daily InsulinTime frame: 6 months
  • AddedHbA1c <53 mmol/Mol (<7.0%)Time frame: 6 months
  • AddedHbA1c <58 mmol/Mol (<7.5%)Time frame: 6 months
  • AddedRelative Reduction ≥10%Time frame: 6 months
  • AddedHbA1c Absolute Reduction ≥0.5%Time frame: 6 months
  • AddedHbA1c Absolute Reduction ≥1%Time frame: 6 months
  • AddedHbA1c Absolute Reduction ≥1% or HbA1c <53 mmol/Mol (<7.0%)Time frame: 6 months
  • RemovedCoefficient of variation of glucose levelsTime frame: 6 months
  • RemovedChanges in total basal and bolus insulin doseTime frame: 6 months
  • RemovedAUC of glucose below 3.5mmol/l (63mg/dl)Time frame: 6 months
  • RemovedAUC glucose above 10.0mmol/L (180mg/dL)Time frame: 6 months
  • RemovedHbA1c <7.0%, HbA1c <7.5%, Relative reduction ≥10% from baseline. o Absolute reduction ≥0.5% from baseline o Absolute reduction ≥1% from baseline o Absolute reduction ≥1% from baseline or HbA1c <7.0%Time frame: 6 months
  • Removedother outcomeUtility evaluationTime frame: 6 months
  • Removedother outcomeHuman Factors AssessmentTime frame: 6 months
  • Removedother outcomeHealth Economic EvaluationTime frame: 6 months
  • Descriptionother outcomeSafety Evaluation: how it is measured was reworded
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Results posted
    Enrollment 131→133
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedThe primary outcome is the centralised measurement of glycated haemoglobinGlycated Hemoglobin (HbA1c) at 6 monthsMonths.Time frame: HbA1c will be taken at baseline, 3 and 6 months → HbA1c at 6 months
    Secondary outcomes 7 edited, 7 added, 8 removed, 1 description edited
    What changed in the outcomes
    • EditedTime spentSpent in the target glucose rangeTarget Glucose Range (3.9 to 10mmol/l) (70 to 180mg/dl)Time frame: 6 months
    • EditedTime spent below target glucoseSpent Below Target Glucose (3.9mmol/l)(70mg/dl)Time frame: 6 months
    • EditedTime spent above target glucoseSpent Above Target Glucose (10.0 mmol/l) (180 mg/dl)Time frame: 6 months
    • EditedMean and standard deviation or percentiles sensor glucoseStandard Deviation Sensor GlucoseTime frame: 6 months
    • EditedTime with glucose levelsWith Glucose Levels < 3.5 mmol/l (63 mg/dl)Time frame: 6 months
    • EditedTime with glucose levelsWith Glucose Levels <3.0 mmol/l (54 mg/dl)Time frame: 6 months
    • EditedTime with glucose levelsWith Glucose Levels in significant hyperglycaemiaSignificant Hyperglycaemia (glucose levelsGlucose Levels > 16.7 mmol/l) (300mg/dl)Time frame: 6 months
    • AddedTotal Daily InsulinTime frame: 6 months
    • AddedHbA1c <53 mmol/Mol (<7.0%)Time frame: 6 months
    • AddedHbA1c <58 mmol/Mol (<7.5%)Time frame: 6 months
    • AddedRelative Reduction ≥10%Time frame: 6 months
    • AddedHbA1c Absolute Reduction ≥0.5%Time frame: 6 months
    • AddedHbA1c Absolute Reduction ≥1%Time frame: 6 months
    • AddedHbA1c Absolute Reduction ≥1% or HbA1c <53 mmol/Mol (<7.0%)Time frame: 6 months
    • RemovedCoefficient of variation of glucose levelsTime frame: 6 months
    • RemovedChanges in total basal and bolus insulin doseTime frame: 6 months
    • RemovedAUC of glucose below 3.5mmol/l (63mg/dl)Time frame: 6 months
    • RemovedAUC glucose above 10.0mmol/L (180mg/dL)Time frame: 6 months
    • RemovedHbA1c <7.0%, HbA1c <7.5%, Relative reduction ≥10% from baseline. o Absolute reduction ≥0.5% from baseline o Absolute reduction ≥1% from baseline o Absolute reduction ≥1% from baseline or HbA1c <7.0%Time frame: 6 months
    • Removedother outcomeUtility evaluationTime frame: 6 months
    • Removedother outcomeHuman Factors AssessmentTime frame: 6 months
    • Removedother outcomeHealth Economic EvaluationTime frame: 6 months
    • Descriptionother outcomeSafety Evaluation: how it is measured was reworded
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

12

Registry details

Key details

Study ID
NCT02925299
Responsible party
Sponsor
First posted
Oct 5, 2016
Start date
May 12, 2017
Primary completion
Aug 27, 2020
Completion
Aug 27, 2020
Results posted
Oct 15, 2026
Last update
Oct 15, 2026

Study contacts

Roman Hovorka, PhD
study chair · University of Cambridge
Ajay Thankamony, MD
principal investigator · University of Cambridge
Fiona Campbell, MD
principal investigator · The Leeds Teaching Hospitals NHS Trust
Bruce Buckingham, MD
principal investigator · Stanford University
Stuart Weinzimer, MD
principal investigator · Yale University
Linda DiMeglio, MD
principal investigator · Indiana University
Paul Wadwa, MD
principal investigator · University of Colorado, Denver
Korey Hood, PhD
principal investigator · Stanford University
Dana Goldman, PhD
principal investigator · University of Southern California
Nikki C Davis, MD
principal investigator · Southampton Children's Hospital
Louise Denvir, MD
principal investigator · Nottingham Children's Hospital
Nelly Mauras, MD
principal investigator · Nemours Children's Health System
Rachel Besser, MD
principal investigator · Oxford Children's Hospital
Atrayee Ghatak, MD
principal investigator · Alder Hey Children's NHS Foundation Trust

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion